Skin-lightening effects of a new face care product in patients with melasma

Journal of Cosmetic Dermatology

Volumn 7, Issue 1, 2008, Pages 68-75

  Scherdin, U ^a   Bürger, Anette ^a   Bielfeldt, Stephan ^b   Filbry, Alexander ^a   Weber, Teresa ^c   Schölermann, Andrea ^a   Wigger alberti, Walter ^b   Rippke, Frank ^a   Wilhelm, Klaus Peter ^b  

^a BEIERSDORF AG   (Germany)

^b proDERM ^*  (Germany)

^c Beiersdorf Inc   (United States)

Author keywords

Melasma; Pigmentary disorders; Skin lightening agents

Indexed keywords

LANOLIN ALCOHOL;

ADULT; ARTICLE; CHLOASMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL IMAGING; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; SKIN CARE; SKIN COLOR;

ADULT; ANALYSIS OF VARIANCE; COLORIMETRY; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DRUG COMBINATIONS; FACIAL DERMATOSES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MELANOSIS; MICROSCOPY, VIDEO; MIDDLE AGED; OLEIC ACIDS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; STATISTICS, NONPARAMETRIC; SUNSCREENING AGENTS; TOCOPHEROLS;

EID: 38949134529     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2008.00364.x     Document Type: Article

References (37)

1. Willis I. Cutaneous heat: A potential environmental factor in the development of melasma. Cosmet Dermatol 2004; 17: 387-90.
2. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J 1999; 40: 455-8.
3. Shenoi SD, Davis SV, Rao S, Rao G, Naid S. Dermatoses among paddy field workers - a descriptive, cross-sectional pilot study. Indian J Dermatol Venereol Leprol 2005; 71: 254-8.
4. Rendon MI. Melasma and postinflammatory hyperpigmentation. Cosmet Dermatol 2003; 16 (Suppl. 3): 16-7.
5. Balkrishnan R, McMichael AJ, Camacho FT et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003; 149: 572-7.
6. Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: The pigment trial. J Drugs Dermatol 2004; 3: 377-81.
7. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat 2007; 18: 5-9.
8. Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa Jr D. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol 2003; 42: 153-6.
9. Ortonne J-P, Passeron T. Melanin pigmentary disorders: Treatment update. Dermatol Clin 2005; 23: 209-26.
10. Picardo M, Carrera M. New and experimental treatments of chloasma and other hypermelanoses. Dermatol Clin 2007; 25: 353-62.
11. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmentating agents: An updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006; 19: 550-71.
12. Ortonne J-P. Retinoid therapy of pigmentary disorders. Dermatol Treat 2006; 19: 280-8.
13. Wiechers JW, Groenhof FJ, Wortel VAL, Miller RM, Hindle NA, Drewitt-Barlow A. Octadecenedioic acid for a more even skin tone. Cosm Toilet 2002; 117: 55-68.
14. Wiechers JW, Rawlings AV, Garcia C et al. A new mechanism of action for skin-whitening agents: Binding to the peroxisome proliferators-activated receptor. Int J Cosmet Sci 2005; 27: 123-32.
15. Kimbrough-Green CK, Griffiths CE, Finkel LJ et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical study. Arch Dermatol 1994; 130: 727-33.
16. Taylor SC. Objective and subjective measures of melasma. Cosmet Dermatol 2007; 20: 93-4.
17. Stamatas GN, Zmudska BZ, Kollias N, Beer JZ. Non-invasive measurements of skin pigmentation. Pigment Cell Res 2004; 17: 618-26.
18. Kramer KE, Lopez A, Stefanato CM, Phillips TJ. Exogenous ochronosis. J Am Acad Derm 2000; 42: 869-71.
19. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol 2005; 4: 55-9.
20. Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: A vehicle-controlled clinical trial. J Med Assoc Thai 1999; 82: 868-75.
21. Lee M-H, Kim H-J, Ha D-J, Paik J-H, Kim H-Y. Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci 2002; 17: 518-23.
22. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 2003; 42: 966-72.
23. Levy JL, Pons F, Agopian L, Besson R. A double-blind controlled study of a nonhydroquinone bleaching cream in the treatment of melasma. J Cosmet Dermatol 2005; 4: 272-6.
24. Hurley ME, Guevara IL, Gonzales RM, Panda AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 2002; 138: 1578-82.
25. Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: A comparative study. Dermatol Surg 2002; 28: 828-32.
26. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): Clinical and histological studies. J Dermatol 1998; 25: 587-96.
27. Grimes P, Kelly P, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis 2006; 77: 177-84.
28. Cestari TF, Hexsel D, Viegas ML et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: The MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol 2007; 156 (Suppl. 1): 13-20.
29. Erbil H, Sezer E, Tastan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol 2007; 34: 25-30.
30. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 1993; 129: 415-21.
31. Hakozaki T, Minwalla L, Zhuang J et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002; 147: 20-31.
32. Shigeta Y, Imanaka H, Ando H et al. Skin whitening effect of linoleic acid is enhanced by liposomal formulations. Biol Pharm Bull 2004; 27: 591-4.
33. Boissy RE, Iisscher M, DeLong MA. DeoxyArbutin: A novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 2005; 14: 601-8.
34. Khemis A, Kaiafa A, Quelle-Roussel C, Duteil L, Ortonne JP. Evaluation of efficacy and safety of rucinol serum in patients with melasma: A randomized controlled trial. Br J Dermatol 2007; 156: 997-1004.
35. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54: S272-S281.
36. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with triple combination cream. Am J Clin Dermatol 2006; 7: 223-30.
37. Cestari TF, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol 2007; 6: 36-9.